false 0001759138 0001759138 2024-06-14 2024-06-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
June 14, 2024
Date of Report (Date of earliest event reported)
CABALETTA BIO, INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
001-39103 |
|
82-1685768 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
2929 Arch Street, Suite 600, Philadelphia, PA |
|
19104 |
(Address of principal executive offices) |
|
(Zip Code) |
(267) 759-3100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
Common Stock, par value $0.00001 per share |
|
CABA |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 |
Regulation FD Disclosure |
On June 14, 2024, Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) posted an investor presentation (the “Investor Presentation”) to the “News & Media” section of the Company’s website at www.cabalettabio.com. The Investor Presentation will be used in connection with a conference call and webcast today, June 14, 2024, at 8:00 a.m. ET to review the initial clinical data presented at the EULAR 2024 Congress and provide an update on the RESET clinical development program. A copy of the Investor Presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
On June 14, 2024, the Company issued a Press Release reporting positive initial clinical data from each of the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis™ and RESET-SLE™ trials (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.
On June 14, 2024, the Company also presented a clinical update at the EULAR European Congress of Rheumatology 2024 Industry Symposia. A copy of the slides, which has been published to the “News & Media” section of the Company’s website, is furnished herewith as Exhibit 99.3 to this Current Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On June 14, 2024, the Company issued the Press Release reporting positive initial clinical data from each of the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials. These data were presented today at 8:15 a.m. CEST (2:15 a.m. ET) at a EULAR European Congress of Rheumatology 2024 Industry Symposia session titled “Immune Reset: The Potential of CAR T Cell Therapy to Transform the Treatment of Patients with Autoimmune Disease” in Vienna, Austria.
Cabaletta designed CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, to deeply and transiently deplete CD19-positive B cells following a one-time infusion that may enable a reset of the immune system with the potential for durable remission without chronic therapy in patients with autoimmune diseases. Cabaletta is advancing four Phase 1/2 RESET trials evaluating CABA-201 within a total of ten cohorts with six patients in each cohort. All cohorts are evaluating the same single, weight-based dose of 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide consistent with the dosing regimen used in the academic experience, without a dose escalation requirement.
As of May 28, 2024, the data cut-off date, one patient treated in the immune-mediated necrotizing myopathy (IMNM) cohort in the RESET-Myositis trial had completed three months of follow-up and one patient enrolled in the systemic lupus erythematosus (SLE) non-renal cohort in the RESET-SLE trial had completed one month of follow-up. The patient with IMNM is a 33-year-old male with a two-year history of disease, positive for anti-SRP antibody and who had prior disease-specific therapy that included IVIg, rituximab, methotrexate and glucocorticoids. The patient with SLE is a 26-year-old male with a six-year history of disease, positive for anti-dsDNA antibody and who had prior disease specific therapy that included cyclophosphamide, voclosporin, belimumab, tacrolimus, mycophenolate mofetil, hydroxychloroquine and glucocorticoids. Both patients were administered a one-time infusion of CABA-201 at 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. The primary endpoint of each trial is safety and tolerability within 28 days of infusion. Secondary endpoints include translational assessments and clinical outcomes.
Initial Clinical Data Summary
Safety and Tolerability
|
• |
|
CABA-201 was administered during a four-day hospital stay, as currently required by the protocol, and was generally well-tolerated with no serious adverse events reported for either patient through the follow-up period. |
|
• |
|
No evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade was observed for either patient through the follow-up period. Tocilizumab was not administered for either patient. |
|
• |
|
No infections were observed for either patient through the follow-up period. |
|
• |
|
All chronic maintenance therapy or concomitant medications were discontinued for both patients through the follow-up period, other than a planned prednisone taper for the SLE patient. |
Clinical and Translational Profile
|
• |
|
Complete B cell depletion was observed within 15 days post-infusion with CABA-201 in both patients. Both patients had early, transient leukopenia, as expected with the preconditioning regimen. |
|
• |
|
CAR T cell expansion associated with CABA-201 reached its peak magnitude at day 15 post-infusion in both patients and the magnitude of expansion was consistent with the academic experience with a similar 4-1BB CD19-CAR T construct. |
|
• |
|
At week 12 of follow-up for the IMNM patient, the data show a decline in creatinine kinase from 617 at infusion to 308 and a total improvement score (TIS) of 30, which is consistent with the clinically meaningful improvement seen in the academic experience of a similar 4-1BB CD19-CAR T construct that also recently reported data from an IMNM patient. |
|
• |
|
At week 4 of follow-up for the SLE patient, the data demonstrated an improvement in the SLEDAI-2K (systemic lupus erythematosus disease activity index) score from 26 at baseline to 10. |
|
• |
|
B cell repopulation was observed in the IMNM patient at week 8 with immature, naïve B cell phenotypes as demonstrated by flow cytometry, suggesting potential immune system reset with confirmatory analyses ongoing. |
About the RESET-Myositis™ Trial
The RESET-Myositis™ trial is a Phase 1/2 open-label study of CABA-201 in subjects with active idiopathic inflammatory myopathy (IIM, or myositis), including the subtypes of dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM) and juvenile myositis (JM), each evaluated in individual cohorts. Subjects will receive a one-time infusion of CABA-201 at a dose of 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. Key inclusion criteria for the DM, ASyS and IMNM cohorts include patients between ages 18 to 75 (inclusive), evidence of active disease and disease activity despite prior or current treatment with standard of care treatments. Key exclusion criteria for the DM, ASyS and IMNM cohorts include cancer-associated myositis, significant lung or cardiac impairment, treatment with a B cell depleting agent within the prior approximately six months or treatment with a biologic agent within the prior approximately three months.
About the RESET-SLE™ Trial
The RESET-SLE™ trial is a Phase 1/2 open-label study of CABA-201 in subjects with systemic lupus erythematosus (SLE) and lupus nephritis (LN), each evaluated in individual cohorts. Subjects will receive a one-time infusion of CABA-201 at a dose of 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. Key inclusion criteria include patients between ages 18 to 65 (inclusive), evidence of active disease and disease activity despite prior or current treatment with standard of care treatments. Key exclusion criteria include treatment with a B cell depleting agent within the prior approximately six months or treatment with a biologic agent within the prior approximately three months.
Forward-Looking Statements
The information under this Item 8.01 contains “forward-looking statements” of the Company within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta’s ability to grow its autoimmune pipeline; Cabaletta’s future plans and strategies for its CAAR T and CARTA technologies and the company’s business plans and objectives as a whole; Cabaletta’s expectations around the potential safety and therapeutic benefits of CABA-201, including its belief that CABA-201 may enable an “immune system reset” with the potential for durable remission without chronic therapy in patients with autoimmune diseases; the Company’s advancement of separate Phase 1/2 clinical trials of CABA-201 in patients with SLE, myositis, SSc and gMG and advancement of a RESET-PV sub-study within the
ongoing DesCAARTes trial in PV, including the Company’s expectations for the efficiency of the trial designs and updates related to status, safety data, or otherwise and the expected timing of the related data read-outs; Cabaletta’s ability to accelerate its pipeline, develop meaningful therapies for patients and leverage its research and translational insights; the clinical significance of the initial clinical data read-out at the EULAR 2024 Congress in June 2024 for patients with myositis and SLE treated with CABA-201; Cabaletta’s additional planned initial clinical data read-outs for patients with SSc and gMG treated with CABA-201 or otherwise; Cabaletta’s advancement of the process to activate clinical trial sites and pursue patient enrollment; and Cabaletta’s planned assessment of its DesCAARTes™ and MusCAARTes™ trials.
Any forward-looking statements in this Item 8.01 are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to regulatory filings and potential clearance; the risk that signs of biologic activity or persistence may not inform long-term results; Cabaletta’s ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of CABA-201; the risk that the results observed with the similarly-designed construct employed in academic publications, including due to the dosing regimen, are not indicative of the results we seek to achieve with CABA-201; risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions and public health crises; Cabaletta’s ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and Fast Track Designation or other designations for its product candidates, as applicable; risks related to Cabaletta’s ability to protect and maintain its intellectual property position; risks related to fostering and maintaining successful relationships with Cabaletta’s collaboration and manufacturing partners, including in light of recent legislation; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Cabaletta’s product candidates will not be successfully developed and/or commercialized; and the risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Cabaletta’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta’s other filings with the Securities and Exchange Commission. All information in this Item 8.01 is as of the date of this Current Report on Form 8-K, and the Company undertakes no duty to update this information unless required by law.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CABALETTA BIO, INC. |
|
|
|
|
Date: June 14, 2024 |
|
|
|
By: |
|
/s/ Steven Nichtberger |
|
|
|
|
|
|
Steven Nichtberger, M.D. |
|
|
|
|
|
|
President and Chief Executive Officer |
CABA-201 Initial Clinical Data from
the RESET-Myositis™ & RESET-SLE™ Phase 1/2 Trials JUNE 2024 Exhibit 99.1
Disclaimer The following presentation,
including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in
connection with the presentation (collectively, the “Presentation”) has been prepared by Cabaletta Bio, Inc. (“we,” “us,” “our,” “Cabaletta” or the “Company”) and is made for
informational purposes only. This Presentation does not purport to be a prospectus, to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this Presentation unless stated otherwise,
and this Presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently
becomes available or changes occurring after the date hereof. This Presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and
financial conditions, and include, but are not limited to, express or implied statements regarding our current beliefs, expectations and assumptions regarding: our business, future plans and strategies for our CAAR T and CARTA technologies; our
ability to grow our autoimmune-focused pipeline; the ability to capitalize on and potential benefits resulting from our research and translational insights; including those related to any similarly-designed constructs or dosing regimens; the
anticipated market opportunities for CABA-201 in patients with autoimmune diseases; the Company’s business plans and objectives; our expectations around the potential success and therapeutic benefits of CABA-201, including our belief that
CABA-201 may enable an “immune system reset”; Cabaletta's belief of the potential for CAR T to enable a paradigm shift in autoimmunity, including its potential achieve durable remissions without chronic therapy;; our plans for Phase 1/2
clinical trials of CABA-201 in patients with systemic lupus erythematosus (SLE), myositis, SSc, and generalized myasthenia gravis (gMG), and for advancement of a RESET-PV sub-study within the ongoing DesCAARTes trial in PV, including the timing
thereof, including our anticipated progress, timing of enrollment, expectations for the efficiency of the clinical trial designs, updates related to status, safety data, or otherwise and the expected timing of the related data read-outs, and ability
to leverage our experience in autoimmune cell therapy; our initial clinical data read-out in the first half of 2024 at the EULAR 2024 symposium for patients with myositis and SLE treated with CABA-201; our planned initial clinical data read-out in
the second half of 2024 for patients with SSc and gMG treated with CABA-201 and additional data; our ability to enroll the requisite number of patients, dose each dosing cohort in the intended manner, and advance the trial as planned in our Phase
1/2 clinical trials of CABA-201; the timing any planned regulatory filings for our development programs, including IND applications; the progress and results of our DesCAARTes™ Phase 1 trial, including the significance and impact around
reported safety and clinical and translational data of cohorts from our DesCAARTes™ and MusCAARTes™ Phase 1 trials; Cabaletta's potential to eliminate the need for apheresis by using a simpler collection process to obtain the starting
material for the CABA-201 manufacturing process the therapeutic potential and clinical benefits of our product candidates; the expectation that Cabaletta may improve outcomes for patients suffering from SLE, SSc, myositis, gMG, mucosal pemphigus
vulgaris, MuSK myasthenia gravis, or other autoimmune diseases; the ability of our clinical strategy to reduce risk, maximize reach and accelerate timelines of our Phase 1/2 clinical trials of CABA-201; our ability to successfully complete our
preclinical and clinical studies for our product candidates, including our ability to enroll the requisite number of patients, dose each dosing cohort in the intended manner, and progress the trial; our ability to obtain and maintain regulatory
approval of our product candidates, including our expectations regarding the intended incentives conferred by and ability to retain Orphan Drug Designation and Fast Track Designations for our product candidates, as applicable; our ability to
accelerate our pipeline and to develop meaningful therapies for patients, including in collaboration with academic and industry partners and the ability to optimize such collaborations on our development programs; our ability to contract with
third-party suppliers and manufacturers and retain such manufacturers, whether due to legislative action or otherwise; to implement an enhanced manufacturing process and further develop our internal manufacturing strategy, capabilities and
facilities; our potential commercial opportunities, including value and addressable market, for our product candidates; and our expectations regarding our use of capital and other financial results, including our ability to fund operations into the
first half of 2026. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “would,”
“should” and “could,” and similar expressions or words, identify forward-looking statements. Various risks, uncertainties and assumptions could cause actual results to differ materially from those anticipated or implied in
our forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the success, cost, and timing of our product candidate development activities and preclinical studies and clinical trials, risks related
to our ability to demonstrate sufficient evidence of safety, efficacy and tolerability in our preclinical studies and clinical trials of CABA-201, DSG3-CAART and MuSK-CAART, the risk that the results observed with the similarly-designed construct,
including, but not limited to, due to dosing regimen, are not indicative of the results we seek to achieve with CABA-201, our plans to evaluate additional cohorts in the DesCAARTes™ trial, including a cohort implementing a pre-treatment
regimen, the risk that signs of biologic activity or persistence may not inform long-term results, the risk that persistence observed with effective CD19-CAR T oncology studies in combination with lymphodepletion is not indicative of, or applicable
to, clinical responses in patients with mPV, risks related to clinical trial site activation or enrollment rates that are lower than expected, our ability to protect and maintain our intellectual property position, risks related to our relationships
with third parties, uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, our ability to retain and recognize the intended incentives conferred by any Orphan
Drug Designations and Fast Track Designations, risks related to regulatory filings and potential clearance, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk that the results of
preclinical studies or clinical studies will not be predictive of future results in connection with future studies, and risks related to volatile market and economic conditions and public health crises. New risks and uncertainties may emerge from
time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly,
you are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could cause our actual results to differ materially from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent annual report on Form
10-K, as well as discussions of potential risks, uncertainties, and other important factors in our other and subsequent filings with the Securities and Exchange Commission. Certain information contained in this Presentation relates to or is based on
studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this Presentation, it
has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. The Company is the owner of various trademarks, trade names and service marks.
Certain other trademarks, trade names and service marks appearing in this Presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this Presentation are referred to without the ® and TM symbols,
but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
Today’s Agenda AGENDA TOPIC
SPEAKER CABA-201 Overview Steven Nichtberger, MD Chief Executive Officer Current & Investigational Treatments for Patients with Autoimmune Disease Iain McInnes, MD, FRCP, PhD, FRSE, FMedSci Vice Principal and Head of the College of Medical,
Veterinary and Life Sciences, Muirhead Chair of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow Initial CABA-201 Data in Myositis & Lupus David Chang, MD, MPH, FACR Chief Medical Officer Conclusions Steven
Nichtberger, MD Chief Executive Officer Q&A
4 Designed to replicate and expand on
the academic clinical data that generated interest in the field CABA-201: CD19-CAR T specifically designed for autoimmunity PK, pharmacokinetics; PD, pharmacodynamics, SAEs: serious adverse events Peng, BinghaoJ, et al. Presented at: American
Society Gene and Cell Therapy 26th Annual Meeting; 2023 May 19; Los Angeles, CA. Dai, Zhenyu, et al. Journal of Cellular Physiology. 2021;236(8): 5832-5847. Evaluated as part of CT120, a dual-CD19xCD22 CAR T product candidate under development by
Nanjing IASO Biotherapeutics, Co., Ltd. (IASO Bio). Fully human anti-CD19 binder Similar binding affinity and biologic activity to FMC63, with binding to the same epitopes1,2 Safety data in ~20 oncology patients evaluated and reported by IASO as
part of a dual-CAR3 4-1BB costimulatory domain Same domain as used in academic studies CD3-zeta signaling domain CABA-201 CABA-201 designed to optimize the potential safety and efficacy of CD19-CAR T for patients with autoimmune disease Key
Questions for RESET™ Phase 1/2 Studies Safety of CABA-201 CABA-201 AE profile CRS, ICANS, SAEs Dose selection 1 x 106 cells/kg PK – CAR T persistence PD – B cell depletion Autoantibody reduction Clinical outcomes
Innovative and scalable clinical
strategy with potential for accelerated development path CABA-201 pipeline targeting a broad range of autoimmune diseases RESET™ – REstoring SElf-Tolerance; IMNM – Immune-mediated necrotizing myopathy; SLE – Systemic lupus
erythematosus; Ab – Antibody; AChR – Acetylcholine receptor; gMG – Generalized myasthenia gravis, PV – Pemphigus vulgaris FDA Fast Track Designation received in dermatomyositis, SLE and lupus nephritis, systemic sclerosis,
mucosal pemphigus vulgaris, and MuSK-Ab positive MG. 1. Sub-study incorporated into DesCAARTes™ study. 2. Data cut-off as of 28 May 2024. Program Trial Preclinical Phase 1/2 Pivotal CABA-201 4-1BB CD19-CAR T RESET-Myositis™ CARTA
Chimeric Antigen Receptor T cells for Autoimmunity RESET-SLE™ RESET-SSc™ RESET-MG™ RESET-PV™ Sub-study1 Dermatomyositis Anti-synthetase syndrome IMNM Lupus Nephritis Non-Renal SLE Skin + Organ Cohort AChR-Ab neg. gMG AChR-Ab
pos. gMG Skin Cohort FTD Mucocutaneous & mucosal pemphigus vulgaris Juvenile Myositis Clinical & translational data2 support the selected single dose of CABA-201 at 1 x 106 cells/kg Rheumatology Neurology Dermatology Contains cohort(s)
without preconditioning Pediatric Indication
Acceleration in enrollment anticipated
in 2H24 with initial CABA-201 data & engaged clinical investigators Sites actively recruiting patients in the RESETTM clinical program1 5 patients enrolled across RESET-SLETM & RESET-MyositisTM, with 3 patients enrolled over the last 2
months 18 actively recruiting clinical sites in the U.S. across the RESETTM studies RESET-SScTM and RESET-MGTM trials now open for enrollment 1. As of June 12, 2024. SLE sites Myositis sites SSc sites MG sites
Current & Investigational
Treatments for Patients with Autoimmune Diseases
Broad immunosuppression and chronic
administration often required to achieve partial, transient responses Current therapies for autoimmunity do not achieve drug-free remission (Hematopoietic stem cell transplant has been shown to be curative in systemic sclerosis but has increased
mortality in the first year6) There is a need for durable, effective and safe therapies that reestablish immune tolerance to eliminate the need for long-term therapy5,6 Khoo T, et al. Nat Rev Rheumatol. 2023;19(11):695-712. Octapharma. Accessed June
10, 2024. Hoover PJ, Costenbader KH. Kidney Int. 2016;90(3):487-92. High Unmet Clinical Need in SLE & Myositis Potential for life-threatening complications ~40% of patients with SLE develop LN3,4 ~25% risk of death or ESRD within 10y Incomplete
responses despite chronic therapy High mortality due to lung & cardiac involvement1 Only FDA & EMA-approved therapy is IVIg in DM2 Many patients remain refractory to standard of care therapies – particularly high unmet need in IMNM1
Lupus Current Therapies in Autoimmunity Broad immunosuppression Modest & inconsistent clinical responses Chronic therapy requirements Hahn BH, et al. Arthritis Care Res (Hoboken). 2012; 64(6): 797–808. Rosenblum MD, et al. Sci Transl Med.
2012;4(125):125sr1. Swart J, et al. Nat Rev Rheumatol. 2017;13:244-256. Myositis
Potential for treatment paradigm to
evolve in autoimmunity CAR T therapy has the potential to provide drug-free, durable & reliable responses Promising clinical responses reported in 15 patients with an academic 4-1BB CD19-CAR T1-3 100% Clinical responses in SLE, myositis, SSc off
immunosuppressive therapies 2+ years SLE drug-free remission with single infusion of CD19-CAR T3 Within 7 months Repopulation of naïve B cells post-infusion <7% Rate of CRS more severe than fever (1/15) Rate of ICANS (1/15) What are the
clinical outcomes with autologous 4-1BB CD19-CAR T cell therapy? CRS – Cytokine release syndrome; ICANS – Immune effector cell-associated neurotoxicity syndrome Müller, Fabian, et al. "CD19 CAR T-Cell Therapy in Autoimmune
Disease—A Case Series with Follow-up." New England Journal of Medicine 390.8 (2024): 687-700. The construct utilized in these studies has a similar design to CABA-201, sharing the 4-1BB costimulatory domain, but is a different construct. It
has been publicly reported that one idiopathic inflammatory myopathy subject in this academic study had a reoccurrence of disease following ~18 months of clinical remission. How is CAR T cell therapy designed to reset the immune system? A
‘living drug’ potentially enabling complete B cell depletion in the blood, tissues, lymph nodes & secondary lymphoid organs While autologous CD19-CAR T has potential to deliver drug-free, durable & reliable responses, multiple
other therapeutic modalities may find a role within the future treatment paradigm
Initial CABA-201 Data in Myositis
& Lupus
Phase 1/2 Myositis Study for
CABA-201 CY, cyclophosphamide; EULAR/ACR, European Alliance of Associations for Rheumatology/America College of Rheumatology; FLU, fludarabine; HSCT, hematopoietic stem cell transplantation. TIS, Total Improvement Score. Juvenile idiopathic
inflammatory myopathy (JIIM, juvenile myositis) cohort recently incorporated into trial Key inclusion criteria Age ≥18 and ≤75 with a definite or probable clinical diagnosis of IIM (2017 EULAR/ACR classification criteria) Diagnosis of
antisynthetase syndrome (ASyS), dermatomyositis (DM), or immune-mediated necrotizing myopathy (IMNM) based on presence of serum myositis-specific antibodies Evidence of active disease despite prior or current treatment with standard of care Key
exclusion criteria Cancer-associated myositis Significant lung or cardiac impairment B cell-depleting agent within prior ~6 months Previous CAR T cell therapy and/or HSCT Screening ASyS n ≥6 IMNM cohort n ≥6 DM cohort n ≥6 Day 1
Day 29 Follow-up through year 3 Leukapheresis and CABA-201 production Preconditioning with FLU and CY Single infusion of CABA-201 (1 × 106 cells/kg) Primary endpoint: Incidence and severity of adverse events Secondary endpoints: TIS CK / muscle
enzymes Myositis-specific autoantibody levels Adverse events PK / PD analysis
Phase 1/2 Lupus Study for CABA-201
ANA, antinuclear antibody; SLEDAI-2K, Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index-2K. Key inclusion criteria Age ≥18 to ≤65 with an SLE diagnosis (2019 EULAR/ACR
classification criteria) ANA+ or anti-dsDNA+ at screening For SLE (non-renal) cohort: active, moderate to severe SLE, SLEDAI 2K ≥8 despite standard therapy For Lupus Nephritis cohort: active, biopsy-proven LN class III or IV, ± class V
Key exclusion criteria B cell-depleting agent within prior ~6 months Previous CAR T cell therapy and/or HSCT Presence of kidney disease other than LN Screening LN cohort n ≥6 Day 1 Day 29 Follow-up through year 3 Leukapheresis and CABA-201
production Preconditioning with FLU and CY Single infusion of CABA-201 (1 × 106 cells/kg) Primary endpoint: Incidence and severity of adverse events SLE non-renal cohort n ≥6 Secondary endpoints: SLE disease activity (e.g., SLEDAI-2K)
Complete renal response Adverse events PK / PD analysis Biomarker analyses
Time to B cell repopulation B cell
phenotype3 Autoantibody changes Durability of clinical activity Rate & severity of infection Chronic maintenance / concomitant medications, if any Up to 12+ months Translational & clinical parameters inform framework to evaluate advanced
modalities in autoimmunity Metrics to assess outcomes of B cell depletion in autoimmunity Indicates data being presented for either or both of the first two patients in the RESET clinical program. Illustrative graphic, adapted from Taubmann, J., et
al. "OP0141 Long Term Safety and Efficacy Of CAR-T Cell Treatment in Refractory SLE-Data from the First Seven Patients." (2023): 93-94. Müller, Fabian, et al. "CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up."
New England Journal of Medicine 390.8 (2024): 687-700. Flow phenotyping data; confirmatory analyses ongoing. Following treatment with autologous CD19-CAR T, 6 pts with 12+ mo. of drug-free remission, as reported by Erlangen group2 Infusion 1 mo. 3
mo. 12+ mo. 6 mo. CD19-CAR T Cells Naïve B cells Healthy B cells Autoreactive B cells CAR T & B cell levels1 Translational measures Clinical data Patient experience B cell depletion: Timing & depth CAR T expansion: Magnitude &
timing Rate of CRS more severe than fever Rate & grade of ICANS Rate & severity of infection Hospitalization requirements Apheresis & preconditioning Single vs. multiple infusions Autoantibody changes Vaccine titer changes Inflammatory
marker changes Early efficacy signals Rate & severity of infection Chronic maintenance therapy / concomitant medications, if any Within 1 month ~3 months Metrics of evaluation
Both patients with refractory
disease, including to B cell-targeting antibodies & other agents Baseline characteristics of first two patients in RESET™ trials dsDNA, double-stranded DNA; IMNM, immune-mediated necrotizing myopathy; MMF, mycophenolate mofetil; MMT-8,
manual muscle testing of 8 muscles; MTX, methotrexate; Ro-52, ribonucleoprotein 52; SRP, signal recognition particle. Baseline=pre-preconditioning visit. Disease manifestations were assessed according to Myositis Disease Activity Assessment Tool
(MDAAT) and SLEDAI-2K for myositis and SLE, respectively. RESET-Myositis Patient #1 RESET-SLE Patient #1 Age (years), sex 33, male 26, male Cohort IMNM Non-renal SLE Disease duration ~2 years ~6 years Prior disease-specific therapy IVIG, rituximab,
MTX, glucocorticoids Cyclophosphamide, voclosporin, belimumab, tacrolimus Disease-specific therapy at screening MTX, glucocorticoids MMF, hydroxychloroquine, glucocorticoids Autoantibodies SRP, Ro-52 ANA, dsDNA Disease activity1 MMT-8: 130, CK: 617
SLEDAI-2K: 26 Disease manifestations1,2 Muscle weakness, dysphagia Vasculitis, arthritis, alopecia, hematuria, proteinuria (isolated class V LN), low complement Expanding CD19-CAR T experience in IMNM & SLE IMNM #1 SLE #1
No CRS, ICANS or infections of any
grade reported through follow-up period1 CABA-201 was well-tolerated in initial patients Data cut-off as of 28 May 2024. Protocol requires a minimum of 4-day hospitalization for monitoring. PI-directed taper from 10mg daily prednisone. Grade 4
leukopenia, neutropenia and lymphopenia reported for SLE Patient #1, the Grade 4 cytopenias resolved and were attributed to the preconditioning regimen (fludarabine and cyclophosphamide). RESET-Myositis Patient #1 RESET-SLE Patient #1 Dose of
CABA-201 83 million (1 x 106/kg) CAR+ cells 63 million (1 x 106/kg) CAR+ cells Duration of inpatient monitoring2 4 days 4 days CRS None None ICANS None None Infections None None Hypogammaglobulinemia None None Serious adverse events None None
Concomitant disease-specific therapy Discontinued MTX prior to infusion; Prednisone discontinued day 3 post-infusion Discontinued MMF and HCQ prior to infusion; Ongoing taper from prednisone 10mg daily by 8 weeks3 Duration of follow-up1 84 days 28
days Both patients discharged after 4 days of monitoring post-infusion & neither received tocilizumab Vaccination titers preserved post-infusion, with no reported infections in the duration of follow-up period1 IMNM #1 SLE #1 Adverse
events4
CABA-201 exhibited anticipated
profile of expansion and contraction1 CABA-201 demonstrated expansion & targeted B cell depletion Response appears to be consistent with published data of cryopreserved CAR T products as well as the expansion profile of BCMA-CAR T products in
patients with multiple myeloma, in which the number of target cells is more similar to autoimmune disease than to B cell leukemias and lymphomas.2-6 Shah BD, et al. Lancet. 2021;398(10299):491-502. Awasthi R, et al. Blood Adv. 2020;4(3):560-572.
IMNM #1 SLE #1 Expansion of CAR T cells to anticipated range suggests target engagement Complete B cell depletion achieved by day 15 on flow cytometry Peripheral peak CAR T expansion occurred at approximately 2 weeks & rapid contraction suggests
systemic B cell aplasia was achieved 4.98% of T cells 3.32% of T cells CABA-201 cells/µL Blood 102 101 100 0 −5 0 5 10 15 20 25 30 Days post infusion SLE #1 IMNM #1 Preconditioning CABA-201 infusion CD19+ CD20+ B cells/µL 60 80 60 20
0 −5 0 5 10 15 20 25 30 Days post infusion Munshi NC, et al. N Engl J Med. 2021;384(8):705-716. Cohen AD, et al. Blood Cancer J. 2022;12(2):32. Müller F, et al. N Engl J Med. 2024;390(8):687-700.
Complete B cell depletion achieved
by day 15 on flow cytometry & maintained in context of WBC recovery Systemic B cell depletion with CABA-201 WBC, white blood cell. 1. Nadir of lymphocyte count following fludarabine and cyclophosphamide administration estimated based on
respective product labels.2,3 2. Fludarabine phosphate injection. Prescribing information. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022137s003lbl.pdf. 3. Cyclophosphamide. Prescribing information. 2013.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s112lbl.pdf. B cell depletion was achieved & maintained in follow up or until naïve B cell recovery; early, transient leukopenia observed in both patients, as
expected with preconditioning1 CD19+ CD20+ B cells/µL SLE #1 IMNM #1 Preconditioning CABA-201 infusion 0.0 −5 0 5 10 15 20 25 30 Days post infusion 2.5 5.0 7.5 10.0 103 cells/µL WBC Counts 0 −5 0 5 10 15 20 25 30 Days post
infusion 2 4 6 8 103 cells/µL Neutrophil Counts 0.0 −5 0 5 10 15 20 25 30 Days post infusion 0.5 1.0 1.5 103 cells/µL Lymphocyte Counts 0.0 −5 0 5 10 15 20 25 30 Days post infusion 0.5 1.0 1.5 103 cells/µL Monocyte Counts
60 80 60 20 0 −5 0 5 10 15 20 25 30 Days post infusion CD19+ CD20+ B cell count Leukocyte counts IMNM #1 SLE #1
Antibody reduction & clinical
improvement in disease activity as anticipated with follow-up of 12 weeks1 CK reduction & clinical improvement observed in SRP IMNM Data cut-off as of May 28, 2024. Luminex assay developed and performed by Cabaletta Labs. Qualitative commercial
assay (Myositis Antigen Panel, performed at National Jewish Health Advanced Diagnostic Laboratories) suggests SRP54 antibody remains strongly positive at Week 12; Ro-52 normalizes by week 8. Based on patient’s moderate level of muscle disease
at baseline, mild-moderate disability and limited extramuscular manifestations, the maximum achievable score is 70 points on the 100-point TIS scale. Patient treated in third-party CASTLE Phase I/II basket study, TIS data at Week 12 and 24 provided
via personal communication with and as presented by Dr. Georg Schett at the EULAR 2024 symposium. Müller F, et al. N Engl J Med. 2024;390(8):687-700. IMNM #1 Discontinued all disease-specific therapies Disease markers continuing to trend
positively Patient reported symptoms as much improved Disease activity & improvement measures Quantitative translational assay shows ongoing reduction in SRP & Ro-52 antibodies2,3 12-week TIS consistent with IMNM case report5 Baseline Week 4
ULN U/L 600 400 200 0 Week 8 Week 12 Creatine Kinase Normal strength MMT-8 150 140 130 120 Baseline Week 4 Week 8 Week 12 Score Major Score (points) 100 80 Minor Moderate 60 40 20 Week 24 Baseline Week 12 None TIS RESET-Myositis IMNM #1 patient
treated with CABA-201 IMNM patient in CASTLE basket study5 ASyS patients treated at Univ. Hospital Erlangen via German expanded access program6 Academic published data overlaid for illustrative purposes SRP9 SRP54 SS-A/Ro-52 Week 8 Week 4 Baseline
10000 5000 0 Week 8 Week 4 Baseline 1500 500 2000 Week 12 1000 0 Net MFI Net MFI SRP
0 0 Month 3 Month 6 SLEDAI-2K Score
25 20 30 10 5 15 Academic published data for illustrative purposes 19 Trend toward improvement in disease manifestations with follow up of 4 weeks2 Early efficacy signals in first patient in non-renal SLE cohort1 Patient in non-renal SLE cohort due
to isolated Class V LN. Data cut-off as of 28 May 2024. Baseline and Day 29 SLEDAI-2K score are reflective of disease activity at study visit day. SLE #1 Vasculitis, arthritis and hematuria resolved within 4 weeks despite discontinuation of all
therapies at infusion other than ongoing taper from prednisone 10mg per day Alopecia Low complement Increased DNA binding4 Proteinuria5 Hematuria Arthritis Vasculitis 26 10 20 SLEDAI-2K3 10 0 Baseline Week 4 30 SLE patient #1 Academic SLE data6 4.
Anti-dsDNA antibody titer decreased from 1:40 to 1:10 from Baseline to Week 4. 5. Urine Protein Creatinine Ratio decreased from 1.08 to 0.80 from Baseline to Week 4. 6. SLE patients treated at Univ. Hospital Erlangen via German expanded access
program; Müller F, et al. N Engl J Med. 2024;390(8):687-700.
BAFF B cells Preconditioning
CABA-201 infusion IMNM patient data provides insights supporting tissue-level effects of CAR T B cell repopulation occurred at 2 months in first IMNM patient Data cut-off as of May 28, 2024. IFNγ peak prior to peripheral CABA-201 peak suggests
tissue-resident B cell cytotoxicity Systemic B cell depletion triggers BAFF to encourage bone marrow B cell repopulation IFN T cells Preconditioning CABA-201 infusion CABA-201 cells/µL Blood 102 101 100 0 −5 0 5 10 15 20
25 30 Days post infusion IFN (pg/mL) 150 100 50 0 IMNM #1 15000 10000 5000 0 0 25 50 Days post infusion CD19+ CD20+ B cells/µL BAFF (pg/mL) 80 60 40 20 0
Initial patient phenotyping data
consistent with potential immune system reset; confirmatory analyses ongoing B cell repopulation with naïve B cells BCR, B cell receptor; Note: Flow plot gating reflects CD19+ CD20+ live lymphocytes. 1. Patient received multiple courses of
rituximab, with most recent dose approximately 9 months prior to CABA-201 infusion. 2. Cambier JC, et al. Nat Rev Immunol. 2007;7(8):633-643. Pre-B cell Early Naïve (Transitional) B cell (CD38Hi CD24Hi) Naïve B cell (CD38Med CD24Med)
Mature BCR Igα Igβ Bone marrow Periphery B cell precursors Image adapted from Cambier JC, et al. 2007.2 Pre-plasma/ plasma cell B Cell, % CD20 Baseline CD19 107 106 105 104 0 0 104 106 105 B cells (CD19+, CD20+) 5.08 Week 12 107 106 105
104 0 0 104 106 105 B cells (CD19+, CD20+) 6.56 107 Day 15 107 106 105 104 0 0 104 106 105 B cells (CD19+, CD20+) 0 Week 8 107 106 105 104 0 0 104 106 105 B cells (CD19+, CD20+) 7.02 CD38 CD24 106 105 104 0 0 104 106 105 106 105 104 0 0 104 106 105
106 105 104 0 0 104 106 105 B cell phenotyping data 1 Early Naïve (Transitional) B cell Naïve B cell Remaining CD19+ CD20+ B cells B cell maturation process1 Memory B cell
Conclusions
Key takeaways from initial CABA-201
data in first two patients1 Data cut-off as of 28 May 2024. Müller F, et al. N Engl J Med. 2024;390(8):687-700. Third-party CASTLE Phase I/II basket study. As of June 12, 2024. 18 clinical sites now enrolling patients in the CABA-201
RESET™ program across four trials – myositis, SLE/LN, systemic sclerosis and myasthenia gravis4 CABA-201: Engineered specifically for autoimmune patients at the selected dose based on a construct design and function that is similar to
the academic CD19-CAR T construct2 Safety of CABA-201 Dose selection 1 x 106 cells/kg Clinical & translational data support the selected dose of CABA-201 PK: IFNγ peak prior to peak of CABA-201 suggests tissue-level B cell cytotoxicity PD:
Systemic B cell depletion followed by repopulation with naïve B cells Autoantibody levels: Decline generally consistent with Univ. Hospital Erlangen data2 Clinical & translational data: Improvement consistent with reported CD19-CAR T
data2,3 In the first 2 patients (IMNM & SLE), CABA-201 was well-tolerated No CRS, ICANS or infections reported through follow-up period
24 Realizing the vision to
transform autoimmune disease treatment 1H24: No reported CRS or ICANS in first myositis or SLE patients2 Clinical update on each patient at EULAR symposium2 Evaluating CABA-201 without preconditioning in PV study Advancing program to potentially
eliminate apheresis Securing scalable commercial manufacturing Cash runway into 1H26 Engineered CABA-201 specifically for use in autoimmune patients Leveraging data from an academic 4-1BB CD19-CAR T construct with favorable safety data &
durable, drug free remissions1 Designed & implemented novel Phase 1/2 clinical program to accelerate path to approval No requirement for dose escalation Independent, parallel 6-patient cohorts Broad portfolio of trials in autoimmunity 2H24:
Additional data from myositis & SLE trials Initial clinical data in SSc & gMG trials Initiated CABA-201 dosing in two company-sponsored studies SLE – Systemic lupus erythematosus; SSc – Systemic sclerosis; gMG – Generalized
myasthenia gravis; PV – Pemphigus vulgaris Müller, Fabian, et al. "CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up." New England Journal of Medicine 390.8 (2024): 687-700. The construct utilized in these
studies has a similar design to CABA-201, sharing the 4-1BB costimulatory domain, but is a different construct. Data cut-off as of 28 May 2024.
Q&A
Exhibit 99.2
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201
No CRS, ICANS, infections or serious adverse events observed in either of the first two
patients through data cut-off of May 28, 2024
CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete
B cell depletion observed in both patients by day 15 post-infusion
Improvements in both patients specific disease measures, consistent with academic
experience of a similar 4-1BB CD19-CAR T, suggest emerging
clinical benefit with CABA-
201 while discontinuing all disease-specific therapies other than a planned steroid taper in
one patient
Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a
potential immune system reset
18 sites open and recruiting across four Phase 1/2 RESET trials with 5
patients enrolled as of
June 12, 2024; initial clinical and translational data support continued development of
CABA-201 at the current dose
Company to host live investor conference call and webcast today at 8:00 a.m. ET
PHILADELPHIA, June 14, 2024 Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching
the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported positive initial clinical data from each of the first two patients dosed with CABA-201 in
the Phase 1/2 RESET-Myositis and RESET-SLE trials. These data will be presented today at 8:15 a.m. CEST (2:15 a.m. ET) at a EULAR European Congress of Rheumatology 2024 Industry Symposia session titled
Immune Reset: The Potential of CAR T Cell Therapy to Transform the Treatment of Patients with Autoimmune Disease in Vienna, Austria. Slides from the presentation can be found on the companys website here.
We are encouraged by the initial safety, clinical and translational data from the RESET-Myositis and RESET-SLE
trials which we believe provide important early validation regarding the potential of the selected clinical dose of CABA-201 to enable an immune system reset for patients with autoimmune diseases. By
demonstrating a potentially well-tolerated safety profile along with initial clinical and translational data consistent with the academic experience of a similar 4-1BB
CD19-CAR T construct, we believe CABA-201 may be uniquely positioned to fulfill unmet patient needs across a broad range of autoimmune diseases, said David J.
Chang, M.D., Chief Medical Officer of Cabaletta. With the RESET-SSc and RESET-MG
trials recently opening for enrollment, an additional cohort evaluating patients with juvenile myositis incorporated into the RESET-Myositis trial and the momentum provided by the promising early clinical data, we are looking forward to accelerating
clinical trial enrollment in the RESET clinical program. We continue to expect to report initial clinical data from the Phase 1/2 RESET-SSc and RESET-MG trials as well as additional data from the
RESET-Myositis and RESET-SLE trials in the second half of this year.
Cabaletta designed CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, to deeply and transiently deplete CD19-positive B cells following a one-time infusion that may
enable a reset of the immune system with the potential for durable remission without chronic therapy in patients with autoimmune diseases. Cabaletta is advancing four Phase 1/2 RESET trials evaluating CABA-201
within a total of ten cohorts with six patients in each cohort. All cohorts are evaluating the same single, weight-based dose of 1 x 106 cells/kg, following a preconditioning regimen of
fludarabine and cyclophosphamide consistent with the dosing regimen used in the academic experience, without a dose escalation requirement.
As of
May 28, 2024, the data cut-off date, one patient treated in the immune-mediated necrotizing myopathy (IMNM) cohort in the RESET-Myositis trial had completed three months of
follow-up and one patient enrolled in the systemic lupus erythematosus (SLE) non-renal cohort in the RESET-SLE trial had
completed one month of follow-up. The patient with IMNM is a 33-year-old male with a
two-year history of disease, positive for anti-SRP antibody and who had prior disease-specific therapy that included IVIg, rituximab, methotrexate and glucocorticoids.
The patient with SLE is a 26-year-old male with a six-year history of disease, positive for anti-dsDNA antibody and who had prior
disease specific therapy that included cyclophosphamide, voclosporin, belimumab, tacrolimus, mycophenolate mofetil, hydroxychloroquine and glucocorticoids. Both patients were administered a one-time infusion
of CABA-201 at 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. The primary endpoint of each trial is safety and
tolerability within 28 days of infusion. Secondary endpoints include translational assessments and clinical outcomes.
Initial Clinical Data Summary
Safety and Tolerability
|
|
|
CABA-201 was administered during a
four-day hospital stay, as currently required by the protocol, and was generally well-tolerated with no serious adverse events reported for either patient through the
follow-up period. |
|
|
|
No evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)
of any grade was observed for either patient through the follow-up period. Tocilizumab was not administered for either patient. |
|
|
|
No infections were observed for either patient through the follow-up
period. |
|
|
|
All chronic maintenance therapy or concomitant medications were discontinued for both patients through the follow-up period, other than a planned prednisone taper for the SLE patient. |
Clinical and
Translational Profile
|
|
|
Complete B cell depletion was observed within 15 days post-infusion with
CABA-201 in both patients. Both patients had early, transient leukopenia, as expected with the preconditioning regimen. |
|
|
|
CAR T cell expansion associated with CABA-201 reached its peak magnitude
at day 15 post-infusion in both patients and the magnitude of expansion was consistent with the academic experience with a similar 4-1BB CD19-CAR T construct.
|
|
|
|
At week 12 of follow-up for the IMNM patient, the data show a decline in
creatinine kinase from 617 at infusion to 308 and a total improvement score (TIS) of 30, which is consistent with the clinically meaningful improvement seen in the academic experience of a similar 4-1BB CD19-CAR T construct that also recently reported data from an IMNM patient. |
|
|
|
At week 4 of follow-up for the SLE patient, the data demonstrated an
improvement in the SLEDAI-2K (systemic lupus erythematosus disease activity index) score from 26 at baseline to 10. |
|
|
|
B cell repopulation was observed in the IMNM patient at week 8 with immature naïve B cell phenotypes as
demonstrated by flow cytometry, suggesting potential immune system reset with confirmatory analyses ongoing. |
Investor Conference
Call and Webcast Information
Cabaletta will host a conference call and webcast today, June 14, 2024, at 8:00 a.m. ET to review the initial
clinical data presented at the satellite symposium at the EULAR 2024 Congress and provide an update on the RESET clinical development program. A webcast of the live call can be accessed on the News and Events section of the Companys website at
www.cabalettabio.com. An archived replay will be available on the Companys website.
About the RESET-Myositis Trial
The RESET-Myositis trial is a
Phase 1/2 open-label study of CABA-201 in subjects with active idiopathic inflammatory myopathy (IIM, or myositis), including the subtypes of dermatomyositis (DM), anti-synthetase syndrome (ASyS),
immune-mediated necrotizing myopathy (IMNM) and juvenile myositis (JM), each evaluated in individual cohorts. Subjects will receive a one-time infusion of CABA-201 at a
dose of 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. Key inclusion criteria for the DM, ASyS and IMNM cohorts include patients between ages 18 to 75
(inclusive), evidence of active disease and disease activity despite prior or current treatment with standard of care treatments. Key exclusion criteria for the DM, ASyS and IMNM cohorts include cancer-associated myositis, significant lung or
cardiac impairment, treatment with a B cell depleting agent within the prior approximately six months or treatment with a biologic agent within the prior approximately three months.
About the RESET-SLE Trial
The RESET-SLE trial is a Phase 1/2 open-label study of CABA-201 in subjects with systemic lupus erythematosus (SLE) and lupus nephritis (LN), each evaluated in individual cohorts. Subjects will receive a one-time infusion of CABA-201 at a dose of 1 x 106 cells/kg, following a preconditioning regimen of fludarabine and cyclophosphamide. Key inclusion criteria include patients between
ages 18 to 65 (inclusive), evidence of active disease and disease activity despite prior or current treatment with standard of care treatments. Key exclusion criteria include treatment with a B cell depleting agent within the prior approximately six
months or treatment with a biologic agent within the prior approximately three months.
About CABA-201
CABA-201 is designed to deeply and transiently deplete CD19-positive cells following a one-time infusion, which may
enable an immune system reset with the potential for durable remission without chronic therapy in patients with autoimmune diseases. Cabaletta is evaluating CABA-201 in multiple autoimmune
conditions within five disease-specific company sponsored INDs including myositis (idiopathic inflammatory myopathy, or IIM), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), generalized myasthenia gravis (gMG) and pemphigus vulgaris
(PV; a sub-study to evaluate CABA-201 without preconditioning).
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA platform encompasses two strategies: the CARTA (chimeric antigen receptor
T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human
CD19-CAR T, as the lead product candidate being evaluated in the RESET (REstoring SElf-Tolerance) clinical trials in systemic lupus erythematosus,
myositis, systemic sclerosis and generalized myasthenia gravis and in the RESET-PV sub-study within the
DesCAARTes clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for
mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA platform is designed to develop potentially curative therapies that offer deep and durable
responses for patients with a broad range of autoimmune diseases. Cabaletta Bios headquarters and labs are located in Philadelphia, PA.
Forward-Looking Statements
This press release contains
forward-looking statements of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabalettas ability to grow
its autoimmune pipeline; Cabalettas future plans and strategies for its CAAR T and CARTA technologies and the companys business plans and objectives as a whole; Cabalettas expectations around the potential safety and therapeutic
benefits of CABA-201, including its belief that CABA-201 may enable an immune system reset with the potential for durable remission without chronic therapy
in patients with autoimmune diseases; the Companys advancement of separate Phase 1/2 clinical trials of CABA-201 in patients with SLE, myositis, SSc and gMG and advancement of a RESET-PV sub-study within the ongoing DesCAARTes trial in PV, including the Companys expectations for the efficiency of the trial designs and updates related to status,
safety data, or otherwise and the expected timing of the related data read-outs; Cabalettas ability to accelerate its pipeline, develop meaningful therapies for patients and leverage its research and translational insights; the clinical
significance of the initial clinical data read-out at the EULAR 2024 Congress in June 2024 for patients with myositis and SLE treated with CABA-201; Cabalettas
additional planned initial clinical data read-outs for patients with SSc and gMG treated with CABA-201 or otherwise; Cabalettas advancement of the process to activate clinical trial sites and pursue
patient enrollment; and Cabalettas planned assessment of its DesCAARTes and MusCAARTes trials.
Any forward-looking statements in this press release are based on managements current expectations and beliefs of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related
to regulatory filings and potential clearance; the risk that signs of biologic activity or persistence may not inform long-term results; Cabalettas ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its
preclinical studies and clinical trials of CABA-201; the risk that the results observed with the similarly-designed construct employed in academic publications, including due to the dosing regimen, are not
indicative of the results we seek to achieve with CABA-201; risks related to clinical trial site activation, delays in enrollment
generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial
results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions and public health crises; Cabalettas ability to retain and recognize the intended
incentives conferred by Orphan Drug Designation and Fast Track Designation or other designations for its product candidates, as applicable; risks related to Cabalettas ability to protect and maintain its intellectual property position; risks
related to fostering and maintaining successful relationships with Cabalettas collaboration and manufacturing partners, including in light of recent legislation; uncertainties related to the initiation and conduct of studies and other
development requirements for its product candidates; the risk that any one or more of Cabalettas product candidates will not be successfully developed and/or commercialized; and the risk that the initial or interim results of preclinical
studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabalettas actual
results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Cabalettas most recent annual report on Form 10-K as well as discussions of
potential risks, uncertainties, and other important factors in Cabalettas other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to
update this information unless required by law.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
IMMUNE Reset: The potential of car t
cell therapy to transform the treatment of patients with autoimmune disease Exhibit 99.3
Symposium Speakers Drs Georg Schett
and Carl June are members of Cabaletta Bio’s Scientific Advisory Board. David J. Chang, MD, MPH, FACR Chief Medical Officer Cabaletta Bio Philadelphia, PA Carl H. June, MD Director of the Center for Cellular Immunotherapies Penn Medicine
Philadelphia, PA Georg Schett, MD Vice President Research Friedrich-Alexander Universität [FAU] Erlangen-Nürnberg Erlangen, Germany
8:15 am-8:20 am 8:20 am-8:35 am 8:35
am-8:50 am 8:50 am-9:15 am 9:15 am-9:30 am Welcome and introductions David J. Chang, MD, MPH, FACR Evolving the potential of chimeric antigen receptor (CAR) T cell therapies to autoimmunity Carl H. June, MD Resetting the immune system of patients
with autoimmune disease Georg Schett, MD Unlocking the potential of CD19-CAR T cell therapy in myositis and lupus David J. Chang, MD, MPH, FACR Agenda Questions and answers
Learning Objectives Learn about the
history of CAR T cell therapies in oncology and their potential in autoimmunity Review the role of B cells in autoimmune disease and the potential for CD19-CAR T cell therapy to transform treatment Understand the potential of CD19-CAR T cell therapy
to reset the immune system in myositis and lupus
Evolving the Potential of Chimeric
Antigen Receptor (CAR) T Cell Therapies to Autoimmunity
Engineered T cells that combine the
targeting ability of antibodies with the cell-killing machinery of T cells What Are Chimeric Antigen Receptor (CAR) T Cells? CD, cluster of differentiation; HLA, human leukocyte antigen. June CH, Sadelain M. N Engl J Med. 2018;379;64-73. T CELL
RECEPTOR CHIMERIC ANTIGEN RECEPTOR Target cell T cell T cell receptor Target antigen CD3 CD3 Target antigen Chimeric antigen receptor Targeting domain (antibody fragment) 4-1BB or CD28 (costimulatory domain) Transmembrane domain CD3ζ Target
cell T cell HLA Image adapted from June CH and Sadelain M. 2018. Transmembrane domain
Personalized Manufacturing of CAR T
Cells C&EN Oncology. Accessed June 10, 2024. https://cen.acs.org/pharmaceuticals/oncology/Controlling-CAR-T-scientists-plan/96/i19. Image adapted from C&EN Oncology 2018. T cell source: A patient’s own T cells 1 Leukapheresis: T cells
collected from blood 2 Viral vector T cell Reprogramming: Viral vectors deliver gene encoding CAR 3 CAR T treatment: CAR T cells are infused intravenously 6 Preparation: Standard lymphodepleting preconditioning regimen 5 Preconditioning CAR T cell
Proliferation: CAR T cells expanded in a bioreactor 4
Personalized cell therapy product that
behaves as a ‘living drug’ by fully eliminating target cells in the body1 Considerations and Efficacy Outcomes of CAR T in Cancer FDA, US Food and Drug Administration. 1. Holzinger A, Abken H. Pharmacology. 2022;107(9-10):446-463. 2.
Pietrobon V, et al. Int J Mol Sci. 2021;22(19):10828. 3. Maude SL, et al. N Engl J Med. 2018;378(5):439-448. 4. Schuster SJ, et al. N Engl J Med. 2019;380(1):45-56. 5. Locke FL, et al. Lancet Oncol. 2019;20(1):31-42. 6. Abramson JS, et al. Lancet.
2020;396(10254):839-852. 7. Wang M, et al. N Engl J Med. 2020;382(14):1331-1342. 8. Schuster SJ, et al. Lancet Oncol. 2021;22(10):1403-1415. 9. Neelapu SS, et al. Blood. 2023;141(19):2307-2315. COMPLETE remission rate: 40%-67%3-7 2017 Kymriah
(tisagenlecleucel) 4-1BB CD19-CAR T cells have been FDA approved for lasting remission of B cell cancers1 CAR T is a ‘living drug’1 Engrafts & expands in the body Penetrates across tissues Activated by target cells1 Preconditioning
key in oncology2 Eliminates cytokine sinks Increases CAR T expansion, persistence & activity 2017 Yescarta (axicabtagene ciloleucel) CD28 2020 Tecartus (brexucabtagene autoleucel) CD28 2021 Breyanzi (lisocabtagene maraleucel) 4-1BB LONG-TERM
remission rate: 30%-59%6-9
Familiarity with CAR T-associated AEs
has increased in oncology, enabling potential outpatient administration Common Adverse Events Associated With CAR T Cell Therapy AE, adverse event; BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; CRS, cytokine
release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ICE, immune effector cell encephalopathy; ICP, intracranial pressure. Zhang Y, et al. J Clin Med. 2023;12(19):6124. Grade 1 Grade 2 Grade 3 Grade 4 ICE SCORE 7-9 3-6
0-2 Unarousable/unable to perform ICE DEPRESSED LEVEL OF CONSCIOUSNESS Awakens spontaneously Awakens to voice Awakens only to tactile stimulus Unarousable or requires vigorous tactile stimuli to arouse or coma SEIZURE None None Any clinical seizure
that resolves rapidly or nonconvulsive seizure that resolves with intervention Life-threatening prolonged seizure (>5 min) or repetitive clinical or electrical seizures with no return to baseline in between ELEVATED ICP/CEREBRAL EDEMA None None
Focal/local edema on neuroimaging Diffuse cerebral edema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI palsy; papilledema; or Cushing’s triad MOTOR FINDINGS None None None Deep focal motor weakness such as
hemiparesis or paraparesis Diagram adapted from Zhang Y, et al. 2023. CRS (cytokine release syndrome) ICANS (immune effector cell-associated neurotoxicity syndrome) Examples of standard therapies for CRS and ICANS Corticosteroids Tocilizumab
Supportive care Temperature ≥38°C FEVER with No vasopressors Vasopressor +/- vasopressin HYPOTENSION Multiple vasopressors and/or Low-flow nasal cannula or blow-by High-flow nasal cannula face mask, nonrebreather mask, or Venturi mask
HYPOXIA Positive pressure (CPAP, BiPAP)
Potential Adverse Events After CAR
T Cell Therapy in Cancer 1. Bonifant CL, et al. Mol Ther Oncolytics. 2016;3:16011. 2. Verdun N, Marks P. N Eng J Med. 2024;390(7):584-586. 3. Adkins S. J Adv Pract Oncol. 2019;10(suppl 3):21-28. 4. FDA. Accessed June 10, 2024.
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed. 5. Wu L. Accessed June 10, 2024.
https://endpts.com/jpm24-fdas-peter-marks-says-some-secondary-cancer-cases-after-car-t-therapy-may-be-causal-but-benefits-still-outweigh-risks/. 6. Expediting the Development of Cell and Gene Therapy. Accessed June 10, 2024.
https://www.youtube.com/watch?v=jt3CNgsCXAk. CBER, Center for Biologics Evaluation and Research. Immune response to recombinant (eg, murine) protein Secondary malignancies In November 2023, the FDA reported identifying 22 cases of T cell cancers
that occurred among the 34,000 patients who previously received treatment with CAR T products2 In April 2024, the FDA required approved CAR T products (CD19 and BCMA targeted) to add a boxed warning for T cell malignancy when used in patients
treated for hematologic malignancies4 In January 2024, the Director of FDA’s CBER suggested the risk:benefit profile of CAR T is not in question in oncology or in moving forward development programs in autoimmune diseases5,6 Image adapted from
Bonifant CL, et al. 2016,1 Verdun N and Marks P. 2024,2 Adkins S, et al. 2019.3 Secondary malignancies Insertional oncogenesis Hypogamm. & cytopenias (incl. neutropenia), increasing risk of infection
Product in lymphoma studya Costim
domain CRS ICANS Requiring tocilizumab Requiring steroids All Gr Gr ≥3 All Gr Gr ≥3 Axicabtagene ciloleucel4 CD28 93% 13% 64% 28% 43% 27% Brexucabtagene autoleucel5 CD28 91% 15% 63% 31% 59% 22% Tisagenlecleucel6 4-1BB 58% 22% 21% 12% 14%
10% Lisocabtagene maraleucel7 4-1BB 42% 2% 30% 10% 18% 10% A human CD19 binder and 4-1BB costimulatory domain may be ideal for a CD19-CAR T construct Differences in CD19-CAR T Constructs aSimilar safety outcomes comparing 4-1BB and CD28
costimulatory domains were also demonstrated in patients with B-ALL.8,9 B-ALL, B cell acute lymphoblastic leukemia; Costim, costimulatory. Gr, grade. 1. June CH, Sadelain M. N Engl J Med. 2018;379;64-73. 2. Brekke OH, Sandlie I. Nat Rev Drug Discov.
2003;2(1):52-62. 3. Cappell KM, Kochenderfer JN. Nat Rev Clin Oncol. 2021;18(11):715-727. 4. Neelapu SS, et al. N Engl J Med. 2017;377(26):2531-2544. 5. Wang M, et al. N Engl J Med. 2020;382(14):1331-1342. 6. Schuster SJ, et al. N Engl J Med.
2019;380(1):45-56. 7. Abramson JS, et al. Lancet. 2020;396(10254):839-852. 8. Zhao X, et al. Mol Ther Oncolytics. 2020;18:272-281. 9. Wu L, et al. Cancers (Basel). 2023;15(10):2767. In oncology, a 4-1BB costimulatory domain is associated with a
reduced incidence and severity of CRS and ICANS events6,7 Chimeric Humanized Fully human Approved products (FMC63) Candidates under development with potentially lower risk of immune responses Sources of CAR constructs IMMUNOGENICITY2 Image adapted
from June CH and Sadelain M. 2018.1 Image adapted from Brekke OH and Inger Sandlie. 2003.2
Significant experience with CAR T
in B cell cancers provided the foundation for autoimmune application Success of CAR T in Oncology Established Over Decades 1. Kuwana Y, et al. Biochem Biophys Res Commun. 1987;149(3):960-968. 2. Moritz D, et al. Proc Natl Acad Sci USA.
1994;91:4318-4322. 3. Roberts MR, et al. Blood. 1994;84(9):2878-2889. 4. Krause A, et al. J Exp Med. 1998;188:619-626. 5. Brentjens RJ, et al. Nat Med. 2003;101(4):1637-1644. 6. Imai C, et al. Leukemia. 2004;18:676-684. 7. O’Leary MC, et al.
Clin Cancer Res. 2019;25(4):1142-146. 8. Mougiakakos D, et al. N Engl J Med. 2021;385(6):567-569. 9. Krishnamurthy A, et al. Wells Fargo, November 2017. 10. Clinicaltrials.gov. Accessed June 10, 2024.
https://clinicaltrials.gov/search?intr=chimeric%20antigen%20receptor. Multiple types of cell therapies are in phase 1/2 studies, with the majority being autologous CAR T cell therapy9 Over 800 ongoing CAR T trials, with the majority in the US and
China10 2017 First CAR T cell therapy approved by FDA (tisagenlecleucel)7 1998 First CD28-costimulated CAR reported4 1994 First report of CAR T cells killing tumor cells in mice2 1994 First clinical trial of CAR T for HIV initiated3 2003 First
anti-CD19 CAR reported5 2004 In an endeavor to improve safety, first 4-1BB-costimulated CAR reported6 2021 First report of CAR T cell therapy for autoimmune disease8 1987 First CAR design1 Experience in oncology has established foundation for
application in autoimmune disease
Factors that predict adverse events
and relapse are minimized in autoimmune diseases1 Considerations for CAR T Therapy in Cancer and Autoimmunity TME, tumor microenvironment. 1. Baker DJ, et al. Nature. 2023;619(7971):707-715. 2. Sterner RC, Sterner RM. Blood Cancer J. 2021;11(4):69.
3. Breyanzi. Prescribing information; 2024. 4. Yescarta. Prescribing information; 2024. 5. Kymriah. Prescribing information; 2022. 6. Müller F, et al. N Engl J Med. 2024;390(8):687-700. 7. Sender, R et al. PNAS 2023 e2308511120. Diseased cell
Healthy cells CAR T cell Necrotic cell TME Fibroblast Treg Cancer cells Risk of side effects related to target B cell burden1,2 Risk of treatment failure due to mutational load (antigen escape)1,2 Risk of permanent B cell aplasia due to prior bone
marrow damage2 Risk of environmental barriers for CAR T cell infiltration Safety, including CRS, ICANS, and prolonged B cell aplasia3-5 High risk1-5 Anticipated risk of suboptimal outcomes Images adapted from Baker DJ, et al. 2023.1 Lower Risk1,6
Cancer Autoimmune disease Healthy B cells 300 billion cells7 Cancer (DLBCL) ~10 trillion cells
Key Takeaways CAR T cells are
engineered T cells that are designed to combine the targeting ability of antibodies with the cell-killing machinery of T cells1 Key learnings from oncology have the potential to accelerate the adoption of CAR T cell therapy for autoimmune disease2,3
Differences in CD19-CAR T costimulatory domains seem to impact safety in cancer3-5 Many factors that drive adverse events & disease relapse post-CAR T are not at play in autoimmune disease driven by B cells3,6 Potentially lower risk of CRS &
ICANS due to lower B cell burden Evolving the Potential of CAR T Cell Therapies to Autoimmunity 1. Holzinger A, Abken H. Pharmacology. 2022;107(9-10):446-463. 2. Baker DJ, et al. Nature. 2023;619(7971):707-715. 3. Cappell KM, Kochenderfer JN. Nat
Rev Clin Oncol. 2021;18(11):715-727. 4. Davey AS, et al. Cancers. 2021;13(38). 5. Zhao X, et al. Molecular Therapy Oncolytics. 2020;18. 6. Müller F, et al. N Engl J Med. 2024;390(8):687-700.
Resetting the Immune System of
Patients With Autoimmune Disease
B Cells Play a Central Role in the
Pathogenesis of Autoimmune Diseases B cells contribute to autoimmunity through a variety of mechanisms1,2 Autoantibody production Antigen presentation T cell co-stimulation Production of proinflammatory cytokines While circulating B cells are
sensitive to depletion, tissue-resident B cells easily escape depletion2 BCR, B cell receptor; MHC, major histocompatibility complex. 1. Barnas JL, et al. Curr Opin Immunol. 2019;61:92-99. 2. Rubin SJS, et al. Nat Rev Rheumatol. 2019;15(5):303-315.
Images adapted from Rubin SJS, et al. 20192 Autoantibodies BCR Autoantigen Autoreactive B cell Cytokines MHC class II TCR Autoreactive T cell Autoantibody production Cytokine production Antigen presentation CD80 or CD86 CD28
Co-stimulation
Current Therapies for B Cell Driven
Autoimmune Disease Rarely Achieve Drug-Free Remission 1. Schett G, et a. Ann Rheum Dis. 2024. PMID: 38777374. 2. Bucci, L. et al. Nat Med. 2024; PMID 38671240. Current challenges Despite good peripheral B cell depletion, bispecific and
antibody-based B cell targeting therapies rarely induce stable drug-free remission in autoimmune disease Shallow B cell depletion that does not tackle resident autoimmune B cell clones may be the reason for this limitation Goals of newer therapies
Deeper B cell depletion with a ‘living drug’ to allow targeting resident autoimmune B cell clones, enabling potential immune tolerance such that long-term drug therapy is not needed Reversibility of B cell depletion enabling a good
safety profile B cells Autoreactive B cells CD19+ plasmablasts CD19- plasma cells CAR T cell mediated B cell depletion Monoclonal antibody Mediated B cell depletion
Emerging Academic Evidence of
CD19-CAR T in Autoimmunity CK: creatinine kinase; Flu/Cy, fludarabine/cyclophosphamide; LN, lupus nephritis; SLE, systemic lupus erythematosus; SLEDAI-2K, systemic lupus erythematosus disease activity index 2K. Müller F, et al. N Engl J Med.
2024;390(8):687-700. 15 patients with refractory systemic autoimmune disease Age range of 18 to 60 years; 60% female All patients with disease duration >12 months All patients had inadequate response to ≥2 lines of therapy ~50% of patients
received B cell depletion therapy Muscle and lung involvement median CK of 4298 U/L Myositis (n=3) Median SLEDAI-2K score of 13; all had LN class III or IV All had active skin and lung involvement SSc (n=4) All patients received a single dose of
1x106/kg CD19-CAR T cells following Flu/Cy preconditioning SLE (n=8)
Preconditioning results in
transient WBC decrease, though B cell depletion is sustained CD19-CAR T Cells Can Result in Targeted B Cell Depletion WBC, white blood cell. Müller F, et al. N Engl J Med. 2024;390(8):687-700. Circulating CAR T cell numbers after CD19-CAR T
treatment (N=15) CD19-CAR T cells Circulating CD19+ B cells within first 10 days after treatment (N=15) Circulating total WBCs within first 30 days after treatment (N=15) CD19+ B cells WBC WBC/µL
Reconstitution With Naïve B
Cells Within 7 Months1 BL, baseline; FU, follow-up; Ig, immunoglobulin; IIM, idiopathic inflammatory myopathy; RC, reconstitution. 1. Müller F, et al. N Engl J Med. 2024;390(8):687-700. 2. Mackensen, Andreas A, et al. Nature Medicine.
2022;28(10):1-9. B cell reconstitution Circulating B cell numbers after CD19-CAR T treatment (N=15)1 Changes in B cell subtype numbers from baseline to B cell reconstitution (n=5)2 Distribution of heavy chain in the BCRs at baseline and after B cell
reconstitution by mRNA sequencing (n=5)2
Patients maintained off
immunosuppressive therapies, suggesting an ‘immune reset’ is possible Long-term Efficacy Outcomes With CD19-CAR T Cells Figures adapted from Müller F, et al. 2024. C3, complement component 3; EUSTAR-AI, European Scleroderma Trials
and Research Group activity index; dsDNA, double stranded DNA; mRSS, modified Rodnan skin score; TIS, total improvement score. Müller F, et al. N Engl J Med. 2024;390(8):687-700. Myositis (n=3) SLE (n=8) Achieved initial responses by 3 months
Decreased disease activity by 6 months Achieved response by 6 months Myositis (n=3, ASyS) SLE (n=8) SSc (n=4)
Preliminary academic data suggests
potential slower IMNM improvement due to muscle-predominant disease1,2 Initial HMGCR IMNM Patient Treated With CD19-CAR T1 MMT8 Units 120 100 80 60 0 50 100 150 81-year-old woman with HMGCR IMNM Myositis subtype involving primarily muscle
Manifestations may affect response kinetics Treated with CD19-CAR T in CASTLE study Potential for disease-specific timing & magnitude of response to CD19-CAR T 1. Patient treated in CASTLE Phase I/II basket study. CK and MMT8 data as presented
at the Global Conference on Myositis in March 2024 and TIS data at Week 12 and 24 provided via personal communication with Dr. Georg Schett. 2. Müller F, et al. N Engl J Med. 2024;390(8):687-700. Disease activity & improvement measures U/L
2,000 1,500 1,000 500 0 0 50 100 150 200 CK 200 Week 24 Baseline Week 12 Major 100 80 Minor Moderate 60 40 20 None TIS IMNM patient in CASTLE basket study1 ASyS patients treated at Univ. Hospital Erlangen via German expanded access program2 Score
(points)
AE profile consisted primarily of
fever in 4-1BB costimulatory domain-containing CD19-CAR T Safety & Tolerability of CD19-CAR T in Autoimmunity1 a2 patients (1 SLE, 1 myositis) had preexisting hypogammaglobulinemia due to previous rituximab exposure b1 patient had preexisting
hypogammaglobulinemia. cPneumonia occurred in an SLE patient 7 weeks after CAR T cell therapy. ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; URTI, upper respiratory tract infection. 1. Müller F, et al. N Engl J Med.
2024;390(8):687-700. Hypogammaglobulinemia 5 patients developed hypogamm.a 2 patients required IVIg supplementationb Vaccine titers remained stable Cytokine release syndrome 67% (10 of 15 patients) with only grade 1 (fever) 1 patient with myositis
with grade 2 Preexisting ILD with increased oxygen requirement for 1 day while febrile 6 patients received tocilizumab Infection 1 hospitalization due to pneumoniac All other infections were mild and mostly manifested as URTIs (including COVID) 2
events of herpes zoster reactivation ICANS Possible grade 1 ICANS in 1 ASyS patient Mild dizziness at 2w post-infusion Resolved following oral steroids
Key Takeaways Academic Data
Demonstrates Drug-free and Durable Responses in Patients With Myositis, SLE and SSc 1. Müller F, et al. N Engl J Med. 2024;390(8):687-700. 2. Mackensen, Andreas A, et al. Nat Med. 2022;28(10):1-9. Case series provides preliminary support for
the feasibility, efficacy and safety of a 4-1BB CD19-CAR T in patients with autoimmune disease1,2 Durable disease- and drug-free remission Acute adverse events post-CAR T consisted primarily of fever Repopulation with naïve B cells within 7
months Most infections were mild in severity, with only one case of pneumonia requiring hospitalization
Unlocking the Potential of CD19-CAR
T Cell Therapy in Myositis and Lupus
Designed to replicate and expand on
the academic clinical data that generated interest in the field REstoring SElf-Tolerance (RESET™) Development Program PK, pharmacokinetics; PD, pharmacodynamics, SAEs: serious adverse events 1.Peng, BinghaoJ, et al. Presented at: American
Society Gene and Cell Therapy 26th Annual Meeting; 2023 May 19; Los Angeles, CA. 2. Dai, Zhenyu, et al. Journal of Cellular Physiology. 2021;236(8): 5832-5847. 3. Evaluated as part of CT120, a dual-CD19xCD22 CAR T product candidate under development
by Nanjing IASO Biotherapeutics, Co., Ltd. (IASO Bio). Fully human anti-CD19 binder Similar binding affinity and biologic activity to FMC63, with binding to the same epitopes1,2 Safety data in ~20 oncology patients evaluated and reported by IASO as
part of a dual-CAR3 4-1BB costimulatory domain Same domain as used in academic studies CD3-zeta signaling domain CABA-201 CABA-201 designed to optimize the potential safety and efficacy of CD19-CAR T for patients with autoimmune disease Key
Questions for RESET Phase 1/2 Studies Safety of CABA-201 CABA-201 AE profile CRS, ICANS, SAEs Dose selection 1 x 106 cells/kg PK – CAR T persistence PD – B cell depletion Autoantibody reduction Clinical outcomes
Phase 1/2 Myositis Study for
CABA-2011 CY, cyclophosphamide; EULAR/ACR, European Alliance of Associations for Rheumatology/America College of Rheumatology; FLU, fludarabine; HSCT, hematopoietic stem cell transplantation. TIS, Total Improvement Score. 1. ClinicalTrials.gov.
Accessed June 10, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT06154252. Key inclusion criteria Age ≥18 and ≤75 with a definite or probable clinical diagnosis of IIM (2017 EULAR/ACR classification criteria) Diagnosis of
antisynthetase syndrome (ASyS), dermatomyositis (DM), or immune-mediated necrotizing myopathy (IMNM) based on presence of serum myositis-specific antibodies Evidence of active disease despite prior or current treatment with standard of care Key
exclusion criteria Cancer-associated myositis Significant lung or cardiac impairment B cell-depleting agent within prior ~6 months Previous CAR T cell therapy and/or HSCT Screening ASyS n ≥6 IMNM cohort n ≥6 DM cohort n ≥6 Day 1
Day 29 Follow-up through year 3 Leukapheresis and CABA-201 production Preconditioning with FLU and CY Single infusion of CABA-201 (1 × 106 cells/kg) Primary endpoint: Incidence and severity of adverse events Secondary endpoints: TIS CK / muscle
enzymes Myositis-specific autoantibody levels Adverse events PK/PD analysis Juvenile IIM cohort recently incorporated into trial
Phase 1/2 Lupus Study for CABA-2011
ANA, antinuclear antibody; SELENA-2K, Systemic Lupus Erythematosus Disease Activity Index-2K. 1. ClinicalTrials.gov. Accessed June 10, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT06121297. Key inclusion criteria Age ≥18 to ≤65
with an SLE diagnosis (2019 EULAR/ACR classification criteria) ANA+ or anti-dsDNA+ at screening For SLE (non-renal) cohort: active, moderate to severe SLE, SLEDAI-2K ≥8 despite standard therapy For Lupus Nephritis cohort: active, biopsy-proven
LN class III or IV, ± class V Key exclusion criteria B cell-depleting agent within prior ~6 months Previous CAR T cell therapy and/or HSCT Presence of kidney disease other than LN Screening LN cohort n ≥6 Day 1 Day 29 Follow-up through
year 3 Leukapheresis and CABA-201 production Preconditioning with FLU and CY Single infusion of CABA-201 (1 × 106 cells/kg) Primary endpoint: Incidence and severity of adverse events SLE non-renal cohort n ≥6 Secondary endpoints: SLE
disease activity (e.g., SLEDAI-2K) Complete renal response Adverse events PK/PD analysis Biomarker analyses
Indicates data being presented for
either or both of the first two patients in the RESET™ clinical program. aFlow phenotyping data; confirmatory analyses ongoing. 1. Illustrative graphic, adapted from Taubmann J, et al. OPO141. Abstract presented at: EULAR; May 31, 2023; Milan,
Italy. 2. Müller F, et al. N Engl J Med. 2024;390(8):687-700. Translational & clinical parameters inform framework to evaluate advanced modalities in autoimmunity Metrics To Assess Outcomes of B Cell Depletion In Autoimmunity Time to B cell
repopulation B cell phenotypea Autoantibody changes Durability of clinical activity Rate & severity of infection Chronic maintenance / concomitant medications, if any Up to 12+ months Following treatment with autologous CD19-CAR T, 6 pts with
12+ mo. of drug-free remission, as reported by Erlangen group2 Infusion 1 mo. 3 mo. 12+ mo. CD19-CAR T Cells Naïve B cells Healthy B cells Autoreactive B cells CAR T & B cell levels1 Translational measures Clinical data Patient experience B
cell depletion: Timing & depth CAR T expansion: Magnitude & timing Rate of CRS more severe than fever Rate & grade of ICANS Rate & severity of infection Hospitalization requirements Apheresis & preconditioning Single vs. multiple
infusions Autoantibody changes Vaccine titer changes Inflammatory marker changes Early efficacy signals Rate & severity of infection Chronic maintenance therapy / concomitant medications, if any Within 1 month ~3 months Metrics of
evaluation
IMNM: High Unmet Need & Limited
Therapeutic Options1 DM, dermatomyositis; EMA, European Medicines Agency; ESRD, end-stage renal disease; IMNM, immune-mediated necrotizing myopathy; HMGCR: HMG-CoA reductase 1. Suh J, et al. Muscle Nerve. Published online May 27, 2024.
doi:10.1002/mus.28114. 2. Khoo T, et al. Nat Rev Rheumatol. 2023;19(11):695-712. 3. Patient treated in third-party CASTLE Phase I/II basket study. Idiopathic inflammatory myopathy (IIM, myositis) > IMNM-associated antibodies include anti-SRP
& anti-HMGCR Muscle disease (weakness, elevated CK) predominant No therapies approved by the FDA or EMA for IMNM Often refractory despite combination therapy (e.g., IVIg, rituximab) Immune-mediated necrotizing myopathy Dermatomyositis
Antisynthetase syndrome Cohort for first patient treated with CABA-201 Myositis Prevalence: ~1 million globally2 HMGCR IMNM patient treated in CASTLE CD19-CAR T study with minor response by 3 months improved to major response at 6 months with no
additional therapy3
SLE: Variable Disease Course &
Limited Treatments1-6 LN, lupus nephritis. 1. Tian J, et al. Ann Rheum Dis. 2023;82(3):351-356. 2. Hoover PJ, Costenbader KH. Kidney Int. 2016;90(3):487-92. 3. Benlysta. Package insert. GSK; 2018. 4. Saphnelo. Package Insert. AstraZeneca.
2021. 5. Hahn BH, et al. Arthritis Care Res (Hoboken). 2012; 64(6): 797–808. 6. Aziz F, Chaudhary, K. Curr Clin Pharmacol. 2018;13(1):4-13. 7. Mackensen, Andreas A, et al. Nature Medicine. 2022;28(10):1-9. Cohort for first patient treated with
CABA-201 Highly heterogenous with potentially life-threatening complications Two biologic therapies approved with 52-week efficacy endpoint Incomplete responses & need for long-term therapy very common ~40% with LN, with Class V LN often
resistant to therapy Academic CD19-CAR T data in SLE patients with predominantly renal disease suggest potential for clinical response by 3 months7 > Systemic lupus erythematosus (SLE) SLE Prevalence: >3 million globally1 Non-renal systemic
lupus erythematosus Lupus nephritis
Both patients had refractory
disease, including to B cell-targeting antibodies & other agents Baseline Characteristics of First Two Patients in RESET Trials aBaseline=pre-preconditioning visit. bDisease manifestations were according to Myositis Disease Activity Assessment
Tool (MDAAT) and SLEDAI-2K for myositis and SLE, respectively. dsDNA, double-stranded DNA; IMNM, immune-mediated necrotizing myopathy; MMF, mycophenolate mofetil; MMT-8, manual muscle testing of 8 muscles; MTX, methotrexate; Ro-52, ribonucleoprotein
52; SRP, signal recognition particle. RESET-Myositis Patient #1 RESET-SLE Patient #1 Age (years), sex 33, male 26, male Cohort IMNM Non-renal SLE Disease duration ~2 years ~6 years Prior disease-specific therapy IVIG, rituximab, MTX, glucocorticoids
Cyclophosphamide, voclosporin, belimumab, tacrolimus Disease-specific therapy at screening MTX, glucocorticoids MMF, hydroxychloroquine, glucocorticoids Autoantibodies SRP, Ro-52 ANA, dsDNA Disease activitya MMT-8: 130, CK: 617 SLEDAI-2K: 26 Disease
manifestationsa,b Muscle weakness, dysphagia Vasculitis, arthritis, alopecia, hematuria, proteinuria (isolated class V LN), low complement Expanding CD19-CAR T experience in IMNM & non-renal SLE IMNM #1 SLE #1
No CRS, ICANS or infections
reported through follow-up perioda CABA-201 was Well-tolerated in Initial Patients aData cut-off as of 28 May 2024. bProtocol requires a minimum of 4-day hospitalization for monitoring. cPI-directed taper from 10mg daily prednisone. dGrade 4
leukopenia, neutropenia and lymphopenia reported for SLE Patient #1, the Grade 4 cytopenias resolved and were attributed to the preconditioning regimen (fludarabine and cyclophosphamide). Both patients discharged after 4 days of monitoring
post-infusion & neither received tocilizumab RESET-Myositis Patient #1 RESET-SLE Patient #1 Dose of CABA-201 83 million (1 x 106/kg) CAR+ cells 63 million (1 x 106/kg) CAR+ cells Duration of inpatient monitoringb 4 days 4 days CRS None None
ICANS None None Infections None None Hypogammaglobulinemia None None Serious adverse events None None Concomitant disease-specific therapy Discontinued MTX prior to infusion; Prednisone discontinued day 3 post-infusion Discontinued MMF and HCQ prior
to infusion; Ongoing taper from prednisone 10mg daily by 8 weeksc Duration of follow-upa 84 days 28 days Adverse eventsd IMNM #1 SLE #1
CABA-201 exhibited anticipated
profile of expansion and contraction1-5 CABA-201 Expansion in Anticipated Range aResponse appears to be consistent with published data of cryopreserved CAR T products as well as the expansion profile of BCMA-CAR T products in patients with multiple
myeloma, in which the number of target cells is more similar to autoimmune disease than to B cell leukemias and lymphomas BCMA, B cell maturation antigen. 1. Shah BD, et al. Lancet. 2021;398(10299):491-502. 2. Awasthi R, et al. Blood Adv.
2020;4(3):560-572. 3. Munshi NC, et al. N Engl J Med. 2021;384(8):705-716. 4. Cohen AD, et al. Blood Cancer J. 2022;12(2):32. 5. Müller F, et al. N Engl J Med. 2024;390(8):687-700. Expansion of CAR T cells to anticipated range suggests target
engagement Peripheral peak CAR T expansion occurred at approximately 2 weeksa Rapid contraction suggests systemic B cell aplasia has been achieved IMNM #1 SLE #1 4.98% of T cells 3.32% of T cells SLE #1 IMNM #1 Preconditioning CABA-201 infusion
CABA-201 cells/µL Blood 102 101 100 0 −5 0 5 10 15 20 25 30 Days post infusion
Complete B cell depletion achieved
by day 15 on flow cytometry & maintained in context of WBC recovery Systemic B Cell Depletion With CABA-201 aNadir of lymphocyte count following fludarabine and cyclophosphamide administration estimated based on respective product labels.1,2
WBC, white blood cell. 1. Fludarabine phosphate injection. Prescribing information. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022137s003lbl.pdf. 2.Cyclophosphamide. Prescribing information. 2013.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s112lbl.pdf. IMNM #1 SLE #1 CD19+ CD20+ B cell count Leukocyte counts B cell depletion was achieved & maintained in follow up or until naïve B cell recovery Early,
transient leukopenia observed in both patients, as expected with preconditioninga SLE #1 IMNM #1 Preconditioning CABA-201 infusion 0.0 −5 0 5 10 15 20 25 30 Days post infusion 2.5 5.0 7.5 10.0 103 cells/µL WBC Counts 0 −5 0 5 10 15
20 25 30 Days post infusion 2 4 6 8 103 cells/µL Neutrophil Counts 0.0 −5 0 5 10 15 20 25 30 Days post infusion 0.5 1.0 1.5 103 cells/µL Lymphocyte Counts 0.0 −5 0 5 10 15 20 25 30 Days post infusion 0.5 1.0 1.5 103
cells/µL Monocyte Counts CD19+ CD20+ B cells/µL 60 80 60 20 0 −5 0 5 10 15 20 25 30 Days post infusion
Immunologic Effects of CABA-201
IMNM #1 CABA-201 pharmacokinetics CABA-201 pharmacodynamics IFNγ peak prior to peripheral CABA-201 peak suggests tissue-resident B cell cytotoxicity Systemic B cell depletion triggers BAFF to encourage bone marrow B cell repopulation
IFN T cells Preconditioning CABA-201 infusion BAFF B cells Preconditioning CABA-201 infusion 15000 10000 5000 0 0 Weeks post infusion CD19+ CD20+ B cells/µL BAFF (pg/mL) 80 60 40 20 0 CABA-201 cells/µL Blood 102 101 100 0
−5 0 5 10 15 20 25 30 Days post infusion IFN (pg/mL) 150 100 50 0 Week 8 Week 4
Antibody reduction & clinical
improvement in disease activity as anticipated with follow-up of 12 weeks CK Reduction & Clinical Improvement Observed in SRP IMNM aData cut-off as of 28 May 2024. bLuminex assay developed and performed by Cabaletta Labs. cQualitative commercial
assay (Myositis Antigen Panel, performed at National Jewish Health Advanced Diagnostic Laboratories) suggests SRP54 antibody remains strongly positive at Week 12; Ro-52 normalizes by week 8. dBased on patient’s moderate level of muscle disease
at baseline, mild-moderate disability and limited extramuscular manifestations, the maximum achievable score is 70 points on the 100-point TIS scale. 1. Patient treated in third-party CASTLE Phase I/II basket study, TIS data at Week 12 and 24
provided via personal communication with and as presented by Dr. Georg Schett. 2. Müller F, et al. N Engl J Med. 2024;390(8):687-700. SRP9, signal recognition particle 9; SSA, Sjögren’s syndrome–related antigen A autoantibody;
TRIM21, tripartite motif 21; ULN, upper limit of normal; CK, creatine kinase. IMNM #1 Quantitative translational assay shows ongoing reduction in SRP & Ro-52 antibodiesb,c SRP9 SRP54 SS-A/Ro-52 Week 8 Week 4 Baseline 10000 5000 0 Discontinued
all disease-specific therapies Disease markers continuing to trend positively Patient reported symptoms as much improved 12-week TIS consistent with IMNM case report1 Disease activity & improvement measures Baseline Week 4 ULN U/L 600 400 200 0
Week 8 Week 12 Creatine Kinase Normal strength MMT-8 150 140 130 120 Baseline Week 4 Week 8 Week 12 Score Week 8 Week 4 Baseline 1500 500 2000 Week 12 1000 0 Net MFI Net MFI SRP Score (points) Major 100 80 Minor Moderate 60 40 20 Week 24 Baseline
Week 12 None TIS RESET-Myositis IMNM #1 patient treated with CABA-201 IMNM patient in CASTLE basket study1 ASyS patients treated at Univ. Hospital Erlangen via German expanded access program2 Academic published data overlaid for illustrative
purposes RESET-Myositis IMNM #1 patient-specific TIS ceilingd
Trend toward improvement in disease
manifestations with follow up of 4 weeksb Early Efficacy Signals in Non-Renal SLEa Vasculitis, arthritis and hematuria resolved within 4 weeks despite discontinuation of all therapies at infusion other than ongoing taper from prednisone 10mg per day
aPatient in non-renal SLE cohort due to isolated Class V LN. bData cut-off as of 28 May 2024. cBaseline and Day 29 SLEDAI-2K score are reflective of disease activity at study visit day. dUrine Protein Creatinine Ratio decreased from 1.08 to 0.80
from Baseline to Week 4. eAnti-dsDNA antibody titer decreased from 1:40 to 1:10 from Baseline to Week 4. 1. SLE patients treated at Univ. Hospital Erlangen via German expanded access program; Müller F, et al. N Engl J Med. 2024;390(8):687-700.
SLE #1 Alopecia Low complement Increased DNA bindingd Proteinuriae Hematuria Arthritis Vasculitis 26 10 20 SLEDAI-2Kc Score 10 0 Baseline Week 4 30 SLE patient #1 0 0 Month 3 Month 6 SLEDAI-2K Score Academic SLE data1 25 20 30 10 5 15 Academic
published data for illustrative purposes
CABA-201 Effects on Vaccine &
Infection Antibody Titers Titers preserved post-infusion, with no reported infections in the duration of follow-up perioda aData cut-off as of 28 May 2024. IMNM #1 SLE #1 Streptococcus pneumoniae HSV1 Influenza A G4 EA (H1N1) Sars-CoV-2 Epstein-Barr
virus (EBV) Bordetella pertussis Cytomegalovirus (CMV) Hepatitis B Mumps virus Diphtheria Hepatitis A Rubeola virus (measles) Rubella virus Tetanus SLE patient #1 Baseline Baseline Week 8 Week 4 Week 4 IMNM patient #1 SLE patient #1 Net MFI 105 104
103 102 Net MFI 105 104 103 102
Initial patient phenotyping data
consistent with potential immune system reset; confirmatory analyses ongoing B Cell Repopulation with Naïve B Cells Note: Flow plot gating reflects CD19+ CD20+ live lymphocytes. aPatient received multiple courses of rituximab, with most recent
dose approximately 9 months prior to CABA-201 infusion. BCR, B cell receptor. 1. Cambier JC, et al. Nat Rev Immunol. 2007;7(8):633-643. Pre-B cell Early Naïve (Transitional) B cell (CD38Hi CD24Hi) Naïve B cell (CD38Med CD24Med) Mature BCR
Igα Igβ Bone marrow Periphery B cell precursors IMNM #1 Image adapted from Cambier JC, et al. 2007.1 Pre-plasma/ plasma cell B Cell, % CD20 Baseline CD19 107 106 105 104 0 0 104 106 105 B cells (CD19+, CD20+) 5.08 Week 12 107 106 105 104 0
0 104 106 105 B cells (CD19+, CD20+) 6.56 107 Day 15 107 106 105 104 0 0 104 106 105 B cells (CD19+, CD20+) 0 Week 8 107 106 105 104 0 0 104 106 105 B cells (CD19+, CD20+) 7.02 CD38 CD24 106 105 104 0 0 104 106 105 106 105 104 0 0 104 106 105 106
105 104 0 0 104 106 105 B cell phenotyping data a Early Naïve (Transitional) B cell Naïve B cell Remaining CD19+ CD20+ B cells B cell maturation process1 Memory B cell
Key Takeaways 1. Müller F, et
al. N Engl J Med. 2024;390(8):687-700. 2. Castle Phase 1/2 basket study. CABA-201: Designed for autoimmune patients to optimize the potential product profile of CD19-CAR T Safety: In the first 2 patients (IMNM & SLE), CABA-201 was well-tolerated
No CRS, ICANS or infections reported through follow-up period Dose: Clinical & translational data support the selected dose of CABA-201 PK: IFNγ peak prior to peak of CABA-201 suggests tissue-level B cell cytotoxicity PD: Systemic B cell
depletion followed by repopulation with naïve B cells Autoantibody levels: Decline generally consistent with Univ. Hospital Erlangen data1 Clinical & translational data: Improvement consistent with reported CD19-CAR T data1,2 18 clinical
sites now enrolling patients in the CABA-201 RESET™ program with four trials open – myositis, SLE/LN, systemic sclerosis and myasthenia gravis
Questions & Answers
You are invited to stop by at Booth
S18-19 for additional engagement with Cabaletta Bio! Please use the EULAR app to complete an evaluation form To learn more, please visit CabalettaBio.com & contact us at clinicaltrials@cabalettabio.com
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Cabaletta Bio (NASDAQ:CABA)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Cabaletta Bio (NASDAQ:CABA)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024